louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05751291: Comparative Study to Evaluate the Efficacy of Ultrasound-Guided Pericapsular Nerve Group (PENG) Block Versus Fascia Iliaca Compartment (FIC) Block on the Postoperative Analgesic Effect in Patients Undergoing Hip Surgeries Under Spinal Anesthesia.
Official title: Comparative Study to Evaluate the Efficacy of Ultrasound-Guided Pericapsular Nerve Group (PENG) Block Versus Fascia Iliaca Compartment (FIC) Block on the Postoperative Analgesic Effect in Patients Undergoing Hip Surgeries Under Spinal Anesthesia.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hip Fractures
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-03-02
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Fractures in and around the hip are quite common irrespective of both the young and elderly population groups and are associated with extreme pain. A hip fracture is a serious injury, with complications that can be life-threatening and is a common orthopedic emergency in the elderly. Early surgery within 48 h of fracture has shown to decrease the complication and mortality rates.


Eligibility criteria: Inclusion Criteria:

* Forty -Two patients above 18 years of age belonging to the American Society of Anaesthesiologists (ASA) physical status Classes I and II scheduled for hip surgery will randomly be allocated into two groups. Group A (PENG block) will receive US - guided PENG block and Group B (FIC block) will receive US - guided FIC block for postoperative pain relief.

Exclusion Criteria:

* Patient refusal.
* Patient with significant neurological, psychiatric or neuromuscular disease.
* Alcoholism.
* Drug abuse.
* Pregnancy or lactating women.
* Suspected Coagulopathy.
* Morbid obesity.
* Known allergy to study medications.
* Septicemia and local infection at the block site.

Primary outcomes:
measure: Comparison between duration of analgesia of Pericapsular Nerve Group (PENG) Block vs Fascia Iliaca Compartment (FIC) Block.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
citation: WERTHEIMER LG. The sensory nerves of the hip joint. J Bone Joint Surg Am. 1952 Apr;34-A(2):477-87. No abstract available.
citation: GARDNER E. The innervation of the hip joint. Anat Rec. 1948 Jul;101(3):353-71. doi: 10.1002/ar.1091010309. No abstract available.
citation: Gerhardt M, Johnson K, Atkinson R, Snow B, Shaw C, Brown A, Vangsness CT Jr. Characterisation and classification of the neural anatomy in the human hip joint. Hip Int. 2012 Jan-Feb;22(1):75-81. doi: 10.5301/HIP.2012.9042.
citation: Short AJ, Barnett JJG, Gofeld M, Baig E, Lam K, Agur AMR, Peng PWH. Anatomic Study of Innervation of the Anterior Hip Capsule: Implication for Image-Guided Intervention. Reg Anesth Pain Med. 2018 Feb;43(2):186-192. doi: 10.1097/AAP.0000000000000701.
Clinical trial NCT02984891: Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
Official title: Dual Imaging Using High-definition Intravascular Ultrasound and Optical Coherence Tomography to Guide Percutaneous Coronary Intervention
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Coronary Artery Disease (CAD)
Keywords: Intravascular ultrasound
Optical coherence tomography
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2016-12-07
Enrollment: 7
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients included in the study will be those with coronary artery disease who are scheduled to undergo standard angiography in the cardiac catheterization lab.

Brief summary: Both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are standardly used and have been extensively studied separately to guide percutaneous coronary intervention and improve long-term outcomes. In this study, the investigators aim to directly compare high-definition IVUS images to OCT in the same patients to determine the differences between each modality as they relate to imaging coronary pathology, with the goal of determining which modality is most appropriate in particular clinical scenarios.

Detailed description: Intravascular ultrasound (IVUS) is an imaging modality that uses ultrasound waves to allow for detailed evaluation of coronary atherosclerotic plaques and the vascular response to coronary interventional devices to guide stent placement during percutaneous coronary intervention. Current conventional IVUS catheters emit ultrasound waves ranging from 20-40 megahertz (mHz), and more recently released high-definition IVUS catheters emit sound waves at 60 mHz, allowing for better image quality, quantitative accuracy, and precision in measurements.

Optical coherence tomography (OCT) is an alternative imaging modality used for similar purposes as IVUS, using a single optical fiber that emits infrared light to image the coronary artery. OCT uses light in the infrared spectrum with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, whereas it is typically 100-200 microns with IVUS. Thus, OCT allows for better image resolution, but this comes at the expense of tissue penetration.

Eligibility criteria: Inclusion criteria:

* Undergone diagnostic coronary angiography
* Evidence of coronary pathology that requires further imaging to guide treatment

Exclusion criteria:

Significant renal insufficiency

Primary outcomes:
measure: Lumen area
timeFrame: Up to 1 hour
measure: Luminal diameter
timeFrame: Up to 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University
state: New York
Study officials:
affiliation: Columbia University
name: Ziad A. Ali, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06016491: The Effect of Acupressure on Menopausal Symptoms
Official title: The Effect of Acupressure on Menopausal Symptoms: A Randomized, Sham Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Menopause
Acupressure
Keywords: Menopause
Acupressure
Menopausal symptoms
Lead sponsor: Mersin University
Sponsor class: OTHER
First posted: 2023-08-29
Enrollment: 81
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a prospective, randomized, placebo-controlled and single-blind study planned to determine the effect of acupressure application on menopausal symptoms.

The hypothesis of the study is that acupressure reduces women's menopausal symptoms.

Detailed description: Menopause is a physiological process during which most women have difficulties and face many problems. Acupressure can be taught and used safely as an effective method to manage the symptoms that women experience during menopause.

This study aims to determine the effect of acupressure on menopausal symptoms. The study has a prospective, randomized, sham-controlled, single-blind design. The research was conducted with 81 women (acupressure n=40, sham acupressure n=41) attending the "Menopause School" in a public hospital in Türkiye between July 05, 2021 and August 02, 2021. Both groups received acupressure application thrice a week for four weeks, 12 sessions in total. The data was obtained using a personal information form and a Menopause Rating Scale.

Eligibility criteria: Inclusion Criteria:

* Able to speak and understand Turkish
* No psychiatric illness
* Natural menopause
* Not on hormone replacement therapy
* Women who volunteered to participate in the study and did not receive any integrated therapy were included.

Exclusion Criteria:

* Those who have undergone menopause with the surgical method
* For lower extremity vascular disease, fracture, sprain or injury, diabetes, cardiovascular disease, thyroid disease, etc. with a diagnosis
* Women who received any integrative therapy were not included in the study.

Primary outcomes:
measure: Menopause Rating Scale (MRS)
timeFrame: Change from before implementation, 0th week and 4th week of practice
Secondary outcomes:
Other outcomes:
Locations:
city: Mersin
country: Turkey
facility: Mersin University
Study officials:
References:
Clinical trial NCT01095991: Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus
Official title: A Randomised, Open, Phase I Study in Patients With Type 2 Diabetes Mellitus Treated With Metformin to Evaluate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin and Vice Versa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes Mellitus
Keywords: Type 2 Diabetes Mellitus, Sitagliptin
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-03-30
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effects of AZD1656 on Sitagliptin pharmacokinetics and vice versa in patients with Type 2 Diabetes Mellitus.


Eligibility criteria: Inclusion Criteria:

* Patients with confirmed type 2 diabetes mellitus for at least 2 months and treated with metformin.
* Body mass index between ≥19 and ≤42 kg/m2.

Exclusion Criteria:

* Intake of another investigational drug within the last 30 days prior to enrolment.
* Clinically significant illness or clinically relevant trauma.

Primary outcomes:
measure: To evaluate the effect of AZD1656 on the steady-state PK of sitagliptin and vice versa by assessment of AUC0-24 and Cmax
timeFrame: Serial PK sampling will be done on Days 5, 10 and 15
Secondary outcomes:
measure: To evaluate the effect of AZD1656 on the steady-state PK of sitagliptin and vice versa by assessment of tmax, t1/2 and CL/F
timeFrame: Serial PK sampling will be done on Days 5, 10 and 15
measure: To evaluate the PK of the AZD1656 and its metabolite when AZD1656 is administered with and without sitagliptin by assessment of AUC0-24, Cmax, tmax and t1/2
timeFrame: Serial PK sampling will be done on Days 5, 10 and 15
measure: To evaluate the safety of AZD1656 with and without sitagliptin by assessment of adverse events (AEs), physical examination, electrocardiogram (ECG), pulse, blood pressure (BP), weight and FPG.
timeFrame: Paper ECG (days 1,2,3,6,7,8,11,16), BP/pulse preentry, every residential day. Weight, physical examination preentry and follow-up. FPG on preentry, day 1,6 and 11.
Other outcomes:
Locations:
city: Neuss
country: Germany
facility: Research Site
Study officials:
affiliation: AstraZeneca Molndal Sweden
name: Stanko Skrtic
role: STUDY_DIRECTOR
affiliation: Profil Institut für Stoffwechselforschung GmbH
name: Christoph Kapitza
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca Molndal Sweden
name: Mirjana Kujacic
role: STUDY_DIRECTOR
References:
Clinical trial NCT01488591: Biomarker Research for Personalized Medicine
Official title: Biomarker Research for Personalized Medicine in Blood Cancer Patient
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hematologic Neoplasms
Lead sponsor: Inje University
Sponsor class: OTHER
First posted: 2011-12-08
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: healthy volunteers

Brief summary: The aim of this study :

1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping


Eligibility criteria: Inclusion Criteria:

* Korean
* Clinical diagnosis of Hematologic neoplasms

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Inje University
Study officials:
References:
Clinical trial NCT05794191: A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
Official title: Assessment of 13-valent Pneumococcal Conjugate Vaccine Effectiveness Among People With HIV
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV
Pneumonia
Infections, Pneumococcal
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2023-04-03
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with HIV in a healthcare administrative database

Brief summary: The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV.

The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream.

All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13.

Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.


Eligibility criteria: Inclusion Criteria:

1. HIV infection defined as at least one inpatient or ≥2 outpatient codes related to HIV at least 30 days but no more than 730 days apart
2. At least 18 years of age at the time of the first HIV-related code
3. At least six months of continuous enrollment in medical and pharmacy plans after the first HIV-related code

Exclusion Criteria:

1. Evidence of PCV13 vaccination before the first HIV-related code

Primary outcomes:
measure: Incidence of invasive pneumococcal disease
timeFrame: July,1 2014 - September 30, 2022 (duration of study)
measure: Incidence of all cause pneumonia
timeFrame: July 1, 2014 - September 30, 2022 (duration of study)
measure: Incidence of pneumococcal pneumonia
timeFrame: July 1, 2014 - September 30, 2022 (duration of study)
Secondary outcomes:
measure: Incidence of pneumococcal pneumonia or unspecified pneumonia
timeFrame: July 1, 2014 - September 30, 2022 (timeframe of study)
measure: Incidence of pneumonia of unspecified causes
timeFrame: July 1, 2014 - September 30, 2022 (timeframe of study)
Other outcomes:
Locations:
city: New York
country: United States
facility: Pfizer
state: New York
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT04427891: Characteristics of Abdominal Fluid in Patients With Diverticulitis Hinchey III or IV
Official title: Study of Changes in Abdominal Fluid in Connection With Peritonitis. A Descriptive Study in Patients With Purulent or Fecal Peritonitis.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Perforated Diverticulitis
Keywords: perforated diverticulitis
peritonitis
protein changes
microbiota
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
Collaborators: name: Göteborg University
First posted: 2020-06-11
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The aim is to study immune responses in patients with perforated divrticulitis leading to peritonitis and emergency surgery. This group will be compared with patients operated for colorectal cancer and patients with uncomplicated (mild) diverticulitis not undergoing surgery.

Brief summary: Perforated diverticulitis of the colon can be complicated by peritonitis, either purulent or fecal. Both are life threatening conditions requiring emergency surgery. The background in terms of reasons for inflammation (diverticulitis) and perforation to develop is unknown. In this study we focus on specific changes associated with inflammation, both in tissues and of fecal and mucosal microbiota.

Detailed description: A prospective study of abdominal fluid, periferal blood, tissues as well as feces in Patients (perforated diverticulitis with peritonitis undergoing emergency surgery, Group I), and in Controls (patients operated due to colorectal cancer, Group II; patients with mild diverticulitis not needing surgery, Group III).

Immune acitvity in abdominal fluid and periferal blood by immunoassay of 92 individual proteins. mRNA expression of 96 specific genes in tissue samples. Quatification of bacterial diversity in feces and colon mucosa.

Eligibility criteria: Inclusion Criteria:

* Signs of perforated diverticulitis with peritonitis and decision to perform emergency surgery (Group I)
* Signs of acute diverticulitis and no decision of emergency surgery (Group II)
* Patients with colorectal cancer planned for elective surgery (Group III)

Exclusion Criteria:

* No surgery performed (Group I and III)
* Withdrawn consent (any group)

Primary outcomes:
measure: inflammatory response
timeFrame: index surgery (Groups I and II)/ emergency room (Group III)
Secondary outcomes:
measure: inflammatory response in tissue
timeFrame: index surgery (Groups I and II)/ emergency room (Group III)
measure: microbiota composition
timeFrame: index surgery (Groups I and II)/ emergency room (Group III)
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Sahlgrenska University Hospital/Östra
state: Västra Götaland Region
Study officials:
affiliation: Sahlgrenska univesitetssjukhuset
name: Eva Haglind, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06341491: The Study of Delay Discounting Among Beneficiaries of the Pé-de-Meia Program
Official title: The Study of Delay Discounting Propensity Among Beneficiaries of the Pé-de-Meia Program: The High School Savings Plan
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Delay Discounting
Lead sponsor: Federal Institute of Education, Science and Technology of the State of Mato Grosso
Sponsor class: OTHER
First posted: 2024-04-02
Enrollment: 120
Sex: ALL
Minimum age (years): 14
Maximum age (years): 24
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Youth between 14 and 24 years of age, duly enrolled in public education institutions and belonging to families that benefit from the Bolsa Família Program.

Brief summary: The aim of this observational study is to explore how the "Pé-de-Meia" Program, a policy of the Brazilian Federal Government designed to encourage the retention and completion of studies by students from low-income families, affects both the students' tendency towards delay discounting and their academic performance. The study seeks to answer the following questions:

How does the "Pé-de-Meia" Program affect the students' propensity for delay discounting? Is there a relationship between the level of delay discounting among students, their academic performance, and school attendance? Participants in the study, high school students enrolled in the "Pé-de-Meia" Program, will undergo assessments to measure their level of delay discounting. The academic performance and school attendance of the participants will be monitored and analyzed in relation to their propensity for delay discounting


Eligibility criteria: Inclusion Criteria:

High school students, Students from public schools; Students from low-income families. -

Exclusion Criteria:

Students with a formal psychological report; students with a formal psychiatric report.

-

Primary outcomes:
measure: Delay discounting
timeFrame: April 2024, July 2024, October 2024, December 2024, February 2025, April 2025, July 2025, October 2025, December 2025
measure: Academic performance - grades
timeFrame: December 2024 and December 2025
measure: School attendance
timeFrame: December 2024 and December 2025
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05289791: Effect of Ultrasonic Activation of Bioceramic Sealer on Postoperative Pain in Lower Premolars
Official title: The Effect of Ultrasonic Activation of Bioceramic Sealer on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Symptomatic Irreversible Pulpitis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-03-21
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to clinically compare post-operative pain levels after ultrasonic activation of Ceraseal bioceramic sealer versus non-activated bioceramic sealer for patients with symptomatic irreversible pulpitis related to mandibular premolar teeth.

Detailed description: To clinically compare post-operative pain levels after ultrasonic activation of Ceraseal bioceramic sealer versus non-activated bioceramic sealer for patients with symptomatic irreversible pulpitis related to mandibular premolar teeth.Ultrasonic activation of Ceraseal bioceramic sealer for 20 seconds using non cutting ultrasonic tip.

Eligibility criteria: Inclusion Criteria:

* Patients above 18 years old and to 50.
* Male or female.
* Patients seeking root canal treatment.
* Mandibular posterior teeth with Symptomatic irreversible pulpitis with preoperative sharp, moderate, or severe pain with normal periapical radiographic appearance or slight widening in lamina dura.
* Systematically healthy patient (ASA I, II).
* Patient who can understand modified VAS and sign informed consent

Exclusion Criteria:

* Medically compromised patients having significant systemic disorders. (ASA III or IV).
* History of intolerance to NSAIDS.
* Patients with two or more adjacent teeth requiring endodontic treatment.
* External root resorption.
* Internal root resorption.
* Vertical root fracture.
* Periapical lesion.
* Association with swelling.
* Acute peri-apical abscess or acute exacerbation of a chronic abscess.
* Pregnancy.
* Use of ibuprofen in the last 12 hour.
* Bleeding disorder.
* Long term corticosteroid use.
* Mobility Grade II or III.
* Pocket depth more than 5mm.
* Previous root canal therapy.
* Non-restorability.
* TMJ problems, bruxism, clenching or traumatic occlusion.
* Inability to perceive the given instructions

Primary outcomes:
measure: postoperative pain
timeFrame: 6 hours
measure: postoperative pain
timeFrame: 12 hours
measure: postoperative pain
timeFrame: 24 hours
measure: postoperative pain
timeFrame: 48 hours
Secondary outcomes:
measure: number of analgesic tablets taken by patient after endodontic treatment
timeFrame: up to 48 hours postoperatively
measure: Sealer Extrusion laterally and periapically
timeFrame: Immediately after obturation.
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo university
state: Manial
Study officials:
affiliation: Cairo University
name: Heba M. El-far, professor
role: STUDY_DIRECTOR
References: